{
  "FullStudy":{
    "Rank":218071,
    "Study":{
      "ProtocolSection":{
        "IdentificationModule":{
          "NCTId":"NCT01513109",
          "OrgStudyIdInfo":{
            "OrgStudyId":"BORLEUWT01"
          },
          "Organization":{
            "OrgFullName":"Jules Bordet Institute",
            "OrgClass":"OTHER"
          },
          "BriefTitle":"Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia",
          "OfficialTitle":"A Phase I/II Study to Assess the Safety and Immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic (ASCI) Combined With Infusions of ex Vivo Regulatory T Cells Depleted T Lymphocytes in in Vivo Regulatory T Cells Depleted Patients as Post-consolidation Therapy for Adult Patients With WT1-positive Acute Myeloid Leukemia (AML) in CR1 (for High Risk Patients) or in CR2 or CR3 Who Are Not Eligible for Allogeneic Stem Cell Transplantation (SCT).",
          "Acronym":"ASCI"
        },
        "StatusModule":{
          "StatusVerifiedDate":"January 2012",
          "OverallStatus":"Unknown status",
          "LastKnownStatus":"Recruiting",
          "ExpandedAccessInfo":{
            "HasExpandedAccess":"No"
          },
          "StartDateStruct":{
            "StartDate":"December 2011"
          },
          "PrimaryCompletionDateStruct":{
            "PrimaryCompletionDate":"December 2013",
            "PrimaryCompletionDateType":"Anticipated"
          },
          "CompletionDateStruct":{
            "CompletionDate":"December 2014",
            "CompletionDateType":"Anticipated"
          },
          "StudyFirstSubmitDate":"January 16, 2012",
          "StudyFirstSubmitQCDate":"January 19, 2012",
          "StudyFirstPostDateStruct":{
            "StudyFirstPostDate":"January 20, 2012",
            "StudyFirstPostDateType":"Estimate"
          },
          "LastUpdateSubmitDate":"January 19, 2012",
          "LastUpdatePostDateStruct":{
            "LastUpdatePostDate":"January 20, 2012",
            "LastUpdatePostDateType":"Estimate"
          }
        },
        "SponsorCollaboratorsModule":{
          "ResponsibleParty":{
            "ResponsiblePartyType":"Sponsor"
          },
          "LeadSponsor":{
            "LeadSponsorName":"Jules Bordet Institute",
            "LeadSponsorClass":"OTHER"
          }
        },
        "OversightModule":{
          "OversightHasDMC":"No"
        },
        "DescriptionModule":{
          "BriefSummary":"The purpose of this study is to evaluate the safety and the efficacy of combined treatment strategy of WT1ASCI, infusion of ex vivo regulatory T cells depleted T lymphocytes and in vivo regulatory T cells depletion as post-consolidation therapy in patients with WT1-positive Acute Myeloid Leukemia. The study will also evaluate the clinical activity and immune response of this approach in bad risk patients in CR1 and all patients in CR2 or CR3, non eligible for an allogeneic Hematopoietic Stem Cell Transplantation",
          "DetailedDescription":"High-risk and intermediate-high risk CR1 AML patients who are not eligible for allo-SCT after chemotherapy have an unfavorable prognosis, and there is currently no treatment able to improve their survival. New approaches to treat these patients are thus urgently needed. Active immunization against tumor antigens is certainly one of these approaches. The tumor antigen targeted in this study is WT1, which is overexpressed and acts as an oncogene in leukemia and several types of solid tumors. WT1-positive acute myeloid Leukemia patients in complete remission (CR) will first undergo two cytaphereses, one of which being frozen, after CD25+ T cell depletion, the second, being frozen unmanipulated as a Treg back-up. Next, patients will be treated for 5 weeks with oral cyclophosphamide according to the so-called \"metronomic regimen\" to achieve in vivo Treg depletion. Patients will thereafter receive WT1 ASCI combined with CD25+ T cell depleted lymphocytes. The total duration of the treatment period will last 48 months (4 years)."
        },
        "ConditionsModule":{
          "ConditionList":{
            "Condition":[
              "Acute Myelogenous Leukemia",
              "Myeloid Leukemia in Remission",
              "Effects of Immunotherapy"
            ]
          },
          "KeywordList":{
            "Keyword":[
              "WT1 positive Acute Myeloid Leukemia",
              "Antigen specific cancer immunotherapeutic",
              "Ex vivo regulatory T cell depletion",
              "In vivo regulatory T cell depletion"
            ]
          }
        },
        "DesignModule":{
          "StudyType":"Interventional",
          "PhaseList":{
            "Phase":[
              "Phase 1",
              "Phase 2"
            ]
          },
          "DesignInfo":{
            "DesignInterventionModel":"Single Group Assignment",
            "DesignPrimaryPurpose":"Treatment",
            "DesignMaskingInfo":{
              "DesignMasking":"None (Open Label)"
            }
          },
          "EnrollmentInfo":{
            "EnrollmentCount":"20",
            "EnrollmentType":"Anticipated"
          }
        },
        "ArmsInterventionsModule":{
          "ArmGroupList":{
            "ArmGroup":[
              {
                "ArmGroupLabel":"Treatment arm",
                "ArmGroupType":"Experimental",
                "ArmGroupDescription":"Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic combined with Treg depletion",
                "ArmGroupInterventionList":{
                  "ArmGroupInterventionName":[
                    "Biological: Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)"
                  ]
                }
              }
            ]
          },
          "InterventionList":{
            "Intervention":[
              {
                "InterventionType":"Biological",
                "InterventionName":"Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)",
                "InterventionDescription":"i.m. administration",
                "InterventionArmGroupLabelList":{
                  "InterventionArmGroupLabel":[
                    "Treatment arm"
                  ]
                }
              }
            ]
          }
        },
        "OutcomesModule":{
          "PrimaryOutcomeList":{
            "PrimaryOutcome":[
              {
                "PrimaryOutcomeMeasure":"Occurence of severe toxicities",
                "PrimaryOutcomeTimeFrame":"4 years"
              }
            ]
          },
          "SecondaryOutcomeList":{
            "SecondaryOutcome":[
              {
                "SecondaryOutcomeMeasure":"Immunogenicity of the WT1 ASCI",
                "SecondaryOutcomeTimeFrame":"4 years"
              }
            ]
          }
        },
        "EligibilityModule":{
          "EligibilityCriteria":"Inclusion Criteria:\n\nThe patient has cytologically proven AML, as defined by the WHO classification. The leukemia is a de novo or a secondary leukemia.\n\nThe patient is in complete morphologic remission Note: Cytogenetic CR (CRc) or molecular CR (CRm) is not required.\n\nAML patients in first complete remission (CR1) who are not eligible for allo-HSCT following the institution's standard of care(except the favourable genetic group subset which is excluded from this study).\nAll AML patients in second or third complete morphological remission(CR2 or CR3) who are not eligible for allo-HSCT.\n\nThe patient received the following therapy according to the institution's standard of care:\n\nFor patients ≤ 60 years old, at least two cycles of intensive chemotherapy (induction and consolidation)\nFor patients > 60 years old, at least one induction chemotherapy. Any patients with severe co-morbidity for which consolidation is unacceptable, can receive only one induction therapy.\nThe patient's blasts cells show over-expression of WT1 transcripts, detected in peripheral blood by qRT-PCR at diagnosis or at first relapse.\nWritten informed consent has been obtained prior to the performance of any protocol-specific procedure.\nThe patient is ≥ 18 years of age at the time of signing of the ICF.\nECOG performance status of 0, 1, or 2 at the time of enrollment.\n\nAdequate hepatic and renal function defined as:\n\nSerum bilirubin < 1.5 times the Upper Limit of Normal (ULN).\nSerum alanine aminotransferase ALAT < 2.5 times the ULN.\nCalculated creatinine clearance > 40 mL/min.\nIf the patient is female, then she must be of non-childbearing potential, i.e., have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal, or if she is of childbearing potential, then she must practice adequate contraception for 30 days prior to treatment administration, have a negative pregnancy test, and continue such precautions for two months after completion of the treatment administration series.\nUnder the investigator criteria, the patient is able to comply with the protocol requirements during the duration of the study.\nIn the investigator's opinion and in compliance with the Institution hematology guidance, the patient should not be eligible for an approved standard of care such as induction with chemotherapy or allo-HSCT.\n\nExclusion Criteria:\n\nThe patient is in morphologic leukemia-free state or in morphologic complete remission but with incomplete blood count recovery as defined by IWG Response Criteria\nThe patient is in CR1 and is in the category of low-risk for relapse patients, i.e. belong to the favourable genetic group subset .\nThe patient was diagnosed with leukemic central nervous system (CNS) disease (E.g. before chemotherapy) or presents neurological symptoms at baseline suggestive of a CNS involvement.\nThe patient has received, is receiving (or is due to receive) allo-HSCT.\nThe patient has (or has had) concomitant malignancies, except effectively treated malignancy that is considered by the investigator highly likely to have been cured.\nThe patient is known to be human immunodeficiency virus (HIV)-positive.\nThe patient has symptomatic autoimmune disease such as, but not limited to, multiple sclerosis, lupus, rheumatoid arthritis and inflammatory bowel disease.\nThe patient has a history of allergic reactions likely to be exacerbated by any component of the study investigational product.\nThe patient has other concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.\nThe patient has congestive heart failure, symptomatic coronary artery disease, or previous myocardial infarction.\nThe patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the study procedures.\nThe patient has received any investigational or non-registered medicinal product other than the study medication within 30 days preceding the first dose of study medication, or plans to receive such a drug during the study period.\nThe patient requires concomitant treatment with systemic corticosteroids or any other immunosuppressive agents. The use of prednisone, or equivalent, < 0.5 mg/kg/day (absolute maximum 40 mg/day), inhaled corticosteroids or topical steroids is permitted.\nThe patient has an active infection and/or is receiving antibiotics. The patient has received i.v. administration of antibiotics within two weeks prior to first study treatment or oral antibiotics within one week prior to first study treatment.\nFor female patients: the patient is pregnant or lactating.",
          "HealthyVolunteers":"No",
          "Gender":"All",
          "MinimumAge":"18 Years",
          "StdAgeList":{
            "StdAge":[
              "Adult",
              "Older Adult"
            ]
          }
        },
        "ContactsLocationsModule":{
          "OverallOfficialList":{
            "OverallOfficial":[
              {
                "OverallOfficialName":"Philippe Martiat, MD PhD",
                "OverallOfficialAffiliation":"Jules Bordet Institute",
                "OverallOfficialRole":"Principal Investigator"
              }
            ]
          },
          "LocationList":{
            "Location":[
              {
                "LocationFacility":"Institut Jules Bordet, tumor center of the Universite Libre de Bruxelles",
                "LocationStatus":"Recruiting",
                "LocationCity":"Brussels",
                "LocationZip":"1000",
                "LocationCountry":"Belgium",
                "LocationContactList":{
                  "LocationContact":[
                    {
                      "LocationContactName":"Catherine Primo, Mrs",
                      "LocationContactRole":"Contact",
                      "LocationContactPhone":"+32 2 541 37 16",
                      "LocationContactEMail":"catherine.primo@bordet.be"
                    },{
                      "LocationContactName":"Redouane Rouas, Mr",
                      "LocationContactRole":"Contact",
                      "LocationContactPhone":"+32 2 541 37 27",
                      "LocationContactEMail":"mrouas@ulb.ac.be"
                    },{
                      "LocationContactName":"Philippe Martiat, MD PhD",
                      "LocationContactRole":"Principal Investigator"
                    }
                  ]
                }
              }
            ]
          }
        },
        "ReferencesModule":{
          "ReferenceList":{
            "Reference":[
              {
                "ReferencePMID":"21322777",
                "ReferenceType":"background",
                "ReferenceCitation":"Alatrash G, Molldrem JJ. Vaccines as consolidation therapy for myeloid leukemia. Expert Rev Hematol. 2011 Feb;4(1):37-50. doi: 10.1586/ehm.10.80. Review."
              },{
                "ReferencePMID":"20529084",
                "ReferenceType":"background",
                "ReferenceCitation":"Barrett AJ, Le Blanc K. Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol. 2010 Aug;161(2):223-32. doi: 10.1111/j.1365-2249.2010.04197.x. Epub 2010 May 31. Review."
              },{
                "ReferencePMID":"19763889",
                "ReferenceType":"background",
                "ReferenceCitation":"Cao X. Regulatory T cells and immune tolerance to tumors. Immunol Res. 2010 Mar;46(1-3):79-93. doi: 10.1007/s12026-009-8124-7. Review."
              },{
                "ReferencePMID":"20501849",
                "ReferenceType":"background",
                "ReferenceCitation":"Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res. 2010 Jun 15;70(12):4850-8. doi: 10.1158/0008-5472.CAN-10-0283. Epub 2010 May 25."
              },{
                "ReferencePMID":"20338811",
                "ReferenceType":"background",
                "ReferenceCitation":"Cao Y, Zhao J, Yang Z, Cai Z, Zhang B, Zhou Y, Shen GX, Chen X, Li S, Huang B. CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. Clin Immunol. 2010 Jul;136(1):21-9. doi: 10.1016/j.clim.2010.02.020. Epub 2010 Mar 24."
              },{
                "ReferencePMID":"20970678",
                "ReferenceType":"background",
                "ReferenceCitation":"Casalegno-Garduño R, Schmitt A, Wang X, Xu X, Schmitt M. Wilms' tumor 1 as a novel target for immunotherapy of leukemia. Transplant Proc. 2010 Oct;42(8):3309-11. doi: 10.1016/j.transproceed.2010.07.034. Review."
              },{
                "ReferencePMID":"19167214",
                "ReferenceType":"background",
                "ReferenceCitation":"Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S, Kallen K, Kiessling R, Schuessler-Lenz M, Singh H, Talmadge J, Zwierzina H, Håkansson L. Improving the efficacy of cancer immunotherapy. Eur J Cancer. 2009 May;45(8):1424-31. doi: 10.1016/j.ejca.2008.12.017. Epub 2009 Jan 21. Review."
              },{
                "ReferencePMID":"19384299",
                "ReferenceType":"background",
                "ReferenceCitation":"Nizar S, Copier J, Meyer B, Bodman-Smith M, Galustian C, Kumar D, Dalgleish A. T-regulatory cell modulation: the future of cancer immunotherapy? Br J Cancer. 2009 Jun 2;100(11):1697-703. doi: 10.1038/sj.bjc.6605040. Epub 2009 Apr 21. Review."
              },{
                "ReferencePMID":"18790445",
                "ReferenceType":"background",
                "ReferenceCitation":"Dao T, Scheinberg DA. Peptide vaccines for myeloid leukaemias. Best Pract Res Clin Haematol. 2008 Sep;21(3):391-404. doi: 10.1016/j.beha.2008.05.001. Review."
              },{
                "ReferencePMID":"22157809",
                "ReferenceType":"background",
                "ReferenceCitation":"Tsuboi A, Oka Y, Kyo T, Katayama Y, Elisseeva OA, Kawakami M, Nishida S, Morimoto S, Murao A, Nakajima H, Hosen N, Oji Y, Sugiyama H. Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease. Leukemia. 2012 Jun;26(6):1410-3. doi: 10.1038/leu.2011.343. Epub 2011 Dec 13."
              },{
                "ReferencePMID":"20031209",
                "ReferenceType":"background",
                "ReferenceCitation":"Tamura H, Dan K, Yokose N, Iwakiri R, Ohta M, Sakamaki H, Tohyama K, Kondo A, Hyodo H, Nakamura K, Yamashita T, Elisseeva OA, Oka Y, Oji Y, Sugiyama H, Ogata K. Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes. Leuk Res. 2010 Aug;34(8):986-90. doi: 10.1016/j.leukres.2009.11.029. Epub 2010 Jan 19."
              },{
                "ReferencePMID":"19120973",
                "ReferenceType":"background",
                "ReferenceCitation":"Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Nakajima H, Elisseeva OA, Harada Y, Li Z, Tatsumi N, Kamino E, Shirakata T, Nishida S, Taniguchi Y, Kawase I, Oji Y, Sugiyama H. A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(+) T cells. Microbiol Immunol. 2008 Dec;52(12):591-600. doi: 10.1111/j.1348-0421.2008.00080.x."
              },{
                "ReferencePMID":"11964293",
                "ReferenceType":"background",
                "ReferenceCitation":"Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH, Soma T, Tamaki H, Kawakami M, Oji Y, Hosen N, Kubota T, Nakagawa M, Yamagami T, Hiraoka A, Tsukaguchi M, Udaka K, Ogawa H, Kishimoto T, Nomura T, Sugiyama H. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood. 2002 May 1;99(9):3272-9."
              },{
                "ReferencePMID":"20955112",
                "ReferenceType":"background",
                "ReferenceCitation":"Elkord E, Alcantar-Orozco EM, Dovedi SJ, Tran DQ, Hawkins RE, Gilham DE. T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther. 2010 Nov;10(11):1573-86. doi: 10.1517/14712598.2010.529126. Review."
              },{
                "ReferencePMID":"20651376",
                "ReferenceType":"background",
                "ReferenceCitation":"Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Tanaka-Harada Y, Hosen N, Nishida S, Shirakata T, Nakajima H, Tatsumi N, Hashimoto N, Taguchi T, Ueda S, Nonomura N, Takeda Y, Ito T, Myoui A, Izumoto S, Maruno M, Yoshimine T, Noguchi S, Okuyama A, Kawase I, Oji Y, Sugiyama H. A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination. Anticancer Res. 2010 Jun;30(6):2247-54."
              },{
                "ReferencePMID":"16960692",
                "ReferenceType":"background",
                "ReferenceCitation":"Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007 May;56(5):641-8. Epub 2006 Sep 8."
              },{
                "ReferencePMID":"20693845",
                "ReferenceType":"background",
                "ReferenceCitation":"Golovina TN, Vonderheide RH. Regulatory T cells: overcoming suppression of T-cell immunity. Cancer J. 2010 Jul-Aug;16(4):342-7. doi: 10.1097/PPO.0b013e3181eb336d. Review."
              },{
                "ReferencePMID":"21150716",
                "ReferenceType":"background",
                "ReferenceCitation":"Ochsenreither S, Fusi A, Busse A, Bauer S, Scheibenbogen C, Stather D, Thiel E, Keilholz U, Letsch A. \"Wilms Tumor Protein 1\" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow. J Immunother. 2011 Jan;34(1):85-91. doi: 10.1097/CJI.0b013e3181f3cc5c."
              },{
                "ReferencePMID":"19389880",
                "ReferenceType":"background",
                "ReferenceCitation":"Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009 Jun 25;113(26):6541-8. doi: 10.1182/blood-2009-02-202598. Epub 2009 Apr 23."
              },{
                "ReferencePMID":"20400682",
                "ReferenceType":"background",
                "ReferenceCitation":"Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss M, Jurcic J, Frattini MG, Scheinberg DA. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 2010 Jul 15;116(2):171-9. doi: 10.1182/blood-2009-10-250993. Epub 2010 Apr 16."
              },{
                "ReferencePMID":"20399961",
                "ReferenceType":"background",
                "ReferenceCitation":"Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. Regulatory T cells in cancer. Adv Cancer Res. 2010;107:57-117. doi: 10.1016/S0065-230X(10)07003-X. Review."
              },{
                "ReferencePMID":"20154220",
                "ReferenceType":"background",
                "ReferenceCitation":"Nakahara T, Uchi H, Lesokhin AM, Avogadri F, Rizzuto GA, Hirschhorn-Cymerman D, Panageas KS, Merghoub T, Wolchok JD, Houghton AN. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood. 2010 Jun 3;115(22):4384-92. doi: 10.1182/blood-2009-11-251231. Epub 2010 Feb 12."
              },{
                "ReferencePMID":"20518016",
                "ReferenceType":"background",
                "ReferenceCitation":"Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010 Aug 15;127(4):759-67. doi: 10.1002/ijc.25429. Review."
              },{
                "ReferencePMID":"1536588",
                "ReferenceType":"background",
                "ReferenceCitation":"Millar MR, MacKay P, Levene M, Langdale V, Martin C. Enterobacteriaceae and neonatal necrotising enterocolitis. Arch Dis Child. 1992 Jan;67(1 Spec No):53-6."
              },{
                "ReferencePMID":"20874639",
                "ReferenceType":"background",
                "ReferenceCitation":"Oka Y, Sugiyama H. WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects. Immunotherapy. 2010 Sep;2(5):591-4. doi: 10.2217/imt.10.58."
              },{
                "ReferencePMID":"19590872",
                "ReferenceType":"background",
                "ReferenceCitation":"Radojcic V, Bezak KB, Skarica M, Pletneva MA, Yoshimura K, Schulick RD, Luznik L. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother. 2010 Jan;59(1):137-48. doi: 10.1007/s00262-009-0734-3. Epub 2009 Jul 10."
              },{
                "ReferencePMID":"21380929",
                "ReferenceType":"background",
                "ReferenceCitation":"Rezvani K. Peptide vaccine therapy for leukemia. Int J Hematol. 2011 Mar;93(3):274-280. doi: 10.1007/s12185-011-0781-3. Epub 2011 Mar 8. Review."
              },{
                "ReferencePMID":"21287325",
                "ReferenceType":"background",
                "ReferenceCitation":"Sakaguchi S. Regulatory T cells: history and perspective. Methods Mol Biol. 2011;707:3-17. doi: 10.1007/978-1-61737-979-6_1. Review."
              },{
                "ReferencePMID":"18058571",
                "ReferenceType":"background",
                "ReferenceCitation":"Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs. 2007 Dec;8(12):1002-8. Review."
              },{
                "ReferencePMID":"21436444",
                "ReferenceType":"background",
                "ReferenceCitation":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011 Mar 25;331(6024):1565-70. doi: 10.1126/science.1203486. Review."
              },{
                "ReferencePMID":"21611872",
                "ReferenceType":"background",
                "ReferenceCitation":"Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol. 2011 Jul;33(4):369-83. doi: 10.1007/s00281-011-0245-0. Epub 2011 May 25. Review."
              },{
                "ReferencePMID":"20631300",
                "ReferenceType":"background",
                "ReferenceCitation":"Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, Gostick E, Vermeulen K, Pieters K, Nijs G, Stein B, Smits EL, Schroyens WA, Gadisseur AP, Vrelust I, Jorens PG, Goossens H, de Vries IJ, Price DA, Oji Y, Oka Y, Sugiyama H, Berneman ZN. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13824-9. doi: 10.1073/pnas.1008051107. Epub 2010 Jul 14."
              },{
                "ReferencePMID":"16313258",
                "ReferenceType":"background",
                "ReferenceCitation":"Wang X, Zheng J, Liu J, Yao J, He Y, Li X, Yu J, Yang J, Liu Z, Huang S. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol. 2005 Dec;75(6):468-76."
              },{
                "ReferencePMID":"19952961",
                "ReferenceType":"background",
                "ReferenceCitation":"Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother. 2010 Jan;33(1):1-7. doi: 10.1097/CJI.0b013e3181b88ffc."
              }
            ]
          }
        }
      },
      "DerivedSection":{
        "MiscInfoModule":{
          "VersionHolder":"April 22, 2020"
        },
        "ConditionBrowseModule":{
          "ConditionMeshList":{
            "ConditionMesh":[
              {
                "ConditionMeshId":"D000007938",
                "ConditionMeshTerm":"Leukemia"
              },{
                "ConditionMeshId":"D000007951",
                "ConditionMeshTerm":"Leukemia, Myeloid"
              },{
                "ConditionMeshId":"D000015470",
                "ConditionMeshTerm":"Leukemia, Myeloid, Acute"
              }
            ]
          },
          "ConditionAncestorList":{
            "ConditionAncestor":[
              {
                "ConditionAncestorId":"D000009370",
                "ConditionAncestorTerm":"Neoplasms by Histologic Type"
              },{
                "ConditionAncestorId":"D000009369",
                "ConditionAncestorTerm":"Neoplasms"
              }
            ]
          },
          "ConditionBrowseLeafList":{
            "ConditionBrowseLeaf":[
              {
                "ConditionBrowseLeafId":"M9528",
                "ConditionBrowseLeafName":"Leukemia",
                "ConditionBrowseLeafAsFound":"Leukemia",
                "ConditionBrowseLeafRelevance":"high"
              },{
                "ConditionBrowseLeafId":"M9538",
                "ConditionBrowseLeafName":"Leukemia, Myeloid",
                "ConditionBrowseLeafAsFound":"Myeloid Leukemia",
                "ConditionBrowseLeafRelevance":"high"
              },{
                "ConditionBrowseLeafId":"M16710",
                "ConditionBrowseLeafName":"Leukemia, Myeloid, Acute",
                "ConditionBrowseLeafAsFound":"Acute Myeloid Leukemia",
                "ConditionBrowseLeafRelevance":"high"
              },{
                "ConditionBrowseLeafId":"M10924",
                "ConditionBrowseLeafName":"Wilms Tumor",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"M10898",
                "ConditionBrowseLeafName":"Neoplasms by Histologic Type",
                "ConditionBrowseLeafRelevance":"low"
              },{
                "ConditionBrowseLeafId":"T4021",
                "ConditionBrowseLeafName":"Myeloid Leukemia",
                "ConditionBrowseLeafAsFound":"Myeloid Leukemia",
                "ConditionBrowseLeafRelevance":"high"
              },{
                "ConditionBrowseLeafId":"T181",
                "ConditionBrowseLeafName":"Acute Myeloid Leukemia",
                "ConditionBrowseLeafAsFound":"Acute Myeloid Leukemia",
                "ConditionBrowseLeafRelevance":"high"
              },{
                "ConditionBrowseLeafId":"T187",
                "ConditionBrowseLeafName":"Acute Non Lymphoblastic Leukemia",
                "ConditionBrowseLeafAsFound":"Acute Myeloid Leukemia",
                "ConditionBrowseLeafRelevance":"high"
              },{
                "ConditionBrowseLeafId":"T5955",
                "ConditionBrowseLeafName":"Wilms' Tumor",
                "ConditionBrowseLeafRelevance":"low"
              }
            ]
          },
          "ConditionBrowseBranchList":{
            "ConditionBrowseBranch":[
              {
                "ConditionBrowseBranchAbbrev":"BC04",
                "ConditionBrowseBranchName":"Cancers and Other Neoplasms"
              },{
                "ConditionBrowseBranchAbbrev":"All",
                "ConditionBrowseBranchName":"All Conditions"
              },{
                "ConditionBrowseBranchAbbrev":"BXS",
                "ConditionBrowseBranchName":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"
              },{
                "ConditionBrowseBranchAbbrev":"BC16",
                "ConditionBrowseBranchName":"Diseases and Abnormalities at or Before Birth"
              },{
                "ConditionBrowseBranchAbbrev":"Rare",
                "ConditionBrowseBranchName":"Rare Diseases"
              }
            ]
          }
        }
      }
    }
  }
}